JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Emricasan (formerly also known as IDN-6556 and PF 03491390) is a potent, first-in-class and irreversible pan-caspase inhibitor. It is in clinical trials for the treatment of liver diseases. Emricasan decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Emricasan facilitates marginal mass islet engraftment in a porcine islet autotransplant model. Oral administration of Emricasan may lower aminotransferase activity in patients with chronic hepatitis C. Oral PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model.
References: Liver Int. 2015 Mar; 35(3):953-66; Transl Stroke Res. 2017 Nov 4.; Surgery. 2011 Jul; 150(1):48-55.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Delivery expected until 6/6/2024
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!